Comparing Allurion Technologies (NYSE:ALUR) & Biotricity (NASDAQ:BTCY)

Allurion Technologies (NYSE:ALUR) and Biotricity (NASDAQ:BTCY) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Allurion Technologies and Biotricity, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	0	0	0	0	N/A
Biotricity	0	1	0	0	2.00

Risk and Volatility

Allurion Technologies has a beta of 0.14, meaning that its share price is 86% less volatile than the S&P 500. Comparatively, Biotricity has a beta of 2.34, meaning that its share price is 134% more volatile than the S&P 500.

Profitability

This table compares Allurion Technologies and Biotricity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	N/A	-23.80%	-16.60%
Biotricity	-146.61%	N/A	-249.45%

Institutional & Insider Ownership

26.5% of Allurion Technologies shares are held by institutional investors. Comparatively, 32.5% of Biotricity shares are held by institutional investors. 20.0% of Allurion Technologies shares are held by insiders. Comparatively, 20.5% of Biotricity shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Allurion Technologies and Biotricity’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$64.42 million	1.81	$32.37 million	N/A	N/A
Biotricity	$10.60 million	0.77	-$18.66 million	($1.59)	-0.60

Allurion Technologies has higher revenue and earnings than Biotricity.

Summary

Allurion Technologies beats Biotricity on 5 of the 9 factors compared between the two stocks.

About Allurion Technologies

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.